Address: Selvita S.A.
Park Life Science
ul. Bobrzyńskiego 14, 30-348 Krakow,Poland
Tel: +48 12 297 47 00
Selvita is a product and solution provider for the pharmaceutical and biotechnology industry. We deliver comprehensive solutions to the customers from pharma & biotech industry targeted at lowering the cost of introducing innovative therapeutical compounds to the market…
Selvita is also the majority shareholder of BioCentrum (www.biocentrum.com.pl), which provides preclinical ADMET services, and biopharmaceutical development services.
Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita is involved in several research projects at the pre-clinical stage. Our current projects are in the area of oncology, central nervous system, and autoimmune disorders
We employ nearly one hundred top-class proffesionals from the area of medicine, chemistry, pharmacy, molecular biology, biotechnology and informatics. Many of our experts have several years of experience in the biotechnology and pharmaceutical companies in the U.S., Canada, UK, Germany and Poland, and publications in the best scientific journals such as: Nature Biotechnology, Science, and the Journal of Medicinal Chemistry. More than thirty employees of the company hold a PhD diploma in the field of biomedical research. We work with leading universities and research centers from Poland, Europe and United States.
In our work we adhere to the highest ethical standards, both in dealing with the environment and within the company. Our goal is to develop solutions that contribute to the extension and improvement of the quality of life. In doing so, Selvita is guided by the respect for human life at it’s every stage, and does not conduct research which violates human dignity.
The areas of our activity include:
• Research on new chemical entities originating from Polish universities or resulting from Selvita’s own discovery programs
• Integrated fee-for-service drug discovery projects based on medicinal chemistry, biology and pharmacology services
• Target-based solutions – advanced protein modeling solutions
• drug discovery – custom in-silico library construction
• lead generation – optimization of lead compounds
• contract synthesis and syntheses paths optimization
• information technology for research projects
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
Selvita is one of Poland’s R&D jewels, and its co-founder and CEO, Paweł Przewięźlikowski, strongly wishes that others would join their efforts in finally raising Poland’s footprint in R&D. He…
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here
